Advanced in Squamous Cell Lung Carcinoma

Manuel J. Cobo

Malaga, AN, ES 
Advanced in Squamous Cell Lung Carcinoma
Malaga, AN, ES 
OverviewLocationsClinical Research

Overview

Manuel Cobo practices in Malaga, Spain. Mr. Cobo is rated as an Advanced expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Squamous Cell Lung Carcinoma, and Heart Transplant.

His clinical research consists of co-authoring 128 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Squamous Cell Lung Carcinoma.

Gender
Male

Locations

Malaga, AN 29010, Spain
Other Locations
Barcelona, CT, Spain
Santander, CB, Spain
Virgen De La Victoria, ML, Spain
Hospital Universitari Dr. Josep Trueta, Las Palmas De Gran Canaria And Hospital Universitario Dr. Balmis Alicante, Alicante, VC, Spain
Granada, AN, Spain
Spain
Puerto Real, AN, Spain
Cadiz, AN 11202, Spain
Algeciras, AN 11202, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drug: Brigatinib
Study Phase: Phase 2
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Carboplatin, Nivolumab
Study Phase: Phase 2
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
Enrollment Status: Terminated
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drug: Alectinib
Study Phase: Phase 2
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
Enrollment Status: Terminated
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Pemetrexed
Study Phase: Phase 2
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Enrollment Status: Terminated
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drug: Atezolizumab+Bevacizumab
Study Phase: Phase 2
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Paclitaxel, Carboplatin
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Drug, Radiation
Study Drug: Osimertinib
Study Phase: Phase 2
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer
Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Drug
A Multicentre, Open-Label, Exploratory Phase Ib Clinical Study to Assess Safety and Efficacy of an EGFR Tyrosine Kinase Inhibitor in Combination With EGF Pathway Targeting Immunisation (EGF-PTI) in Treatment-Naïve Patients With EGFR Mutant NSCLC. The EPICAL Study
A Multicentre, Open-Label, Exploratory Phase Ib Clinical Study to Assess Safety and Efficacy of an EGFR Tyrosine Kinase Inhibitor in Combination With EGF Pathway Targeting Immunisation (EGF-PTI) in Treatment-Naïve Patients With EGFR Mutant NSCLC. The EPICAL Study
Enrollment Status: Completed
Publish Date: June 30, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Enrollment Status: Completed
Publish Date: June 27, 2022
A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain
A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Drug
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Diagnostic test
T790M Mutation Testing in Blood by Different Methodologies_RING Project
T790M Mutation Testing in Blood by Different Methodologies_RING Project
Enrollment Status: Completed
Publish Date: April 08, 2020
Intervention Type: Drug
View 15 Less Clinical Trials

128 Total Publications

Biomarker landscape in advanced NSCLC: insights from a national prospective registry.
Biomarker landscape in advanced NSCLC: insights from a national prospective registry.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cobo's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile